title: Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
abstract: OBJECTIVE
  This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL).
  
  
  METHODS
  A prospective, open-label, single-arm study.
  
  
  METHODS
  11 tertiary centres in Korea.
  
  
  METHODS
  58 Korean patients (aged 21-72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24.
  
  
  METHODS
  We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire.
  
  
  RESULTS
  Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 μg/L, p<0.001; IGF-I: 497 vs 265 μg/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 μg/L; IGF-I: 294 μg/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=-0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period (p=0.047).
  
  
  CONCLUSIONS
  Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
authors.forename: Sang Ouk
authors.initials: SO
authors.lastname: Chin
authors.affiliation: Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Korea.
authors.forename: Choon Hee
authors.initials: CH
authors.lastname: Chung
authors.affiliation: Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
authors.forename: Yoon-Sok
authors.initials: YS
authors.lastname: Chung
authors.affiliation: Department of Endocrinology and Metabolism, Gachon University Gil Medical Center, Incheon, Korea.
authors.forename: Byung-Joon
authors.initials: BJ
authors.lastname: Kim
authors.affiliation: Division of Endocrinology and Metabolism, Department of Endocrinology, Korea University College of Medicine, Seoul, Korea.
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
authors.forename: In-Ju
authors.initials: IJ
authors.lastname: Kim
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook University School of Medicine, Daegu, Korea.
authors.forename: Jung Guk
authors.initials: JG
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
authors.forename: Min-Seon
authors.initials: MS
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Seoul National University School of Medicine, Seoul, Korea.
authors.forename: Seong-Yeon
authors.initials: SY
authors.lastname: Kim
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Eun Jig
authors.initials: EJ
authors.lastname: Lee
authors.affiliation: Department of Endocrinology and Metabolism, Gachon University Gil Medical Center, Incheon, Korea.
authors.forename: Ki Young
authors.initials: KY
authors.lastname: Lee
authors.affiliation: Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
authors.forename: Sung-Woon
authors.initials: SW
authors.lastname: Kim
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D000203:Activities of Daily Living / Q000523:psychology; D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006262:Health; D006304:Health Status; D019382:Human Growth Hormone / Q000097:blood*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D000067029:Physical Appearance, Body; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology; D056910:Republic of Korea; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D015282:Octreotide